Paul Kelly's most recent trade in Relmada Therapeutics Inc was a trade of 828,000 Stock Appreciation Rights done . Disclosure was reported to the exchange on Dec. 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics Inc | Paul Kelly | Director, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 828,000 | 828,000 | - | - | Stock Appreciation Rights | |
| Relmada Therapeutics Inc | Paul Kelly | Director, Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 2.20 per share. | 05 Nov 2025 | 90,000 | 502,295 (3%) | 0% | 2.2 | 198,000 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director, Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.43 per share. | 16 May 2025 | 200,000 | 412,295 (2%) | 1% | 0.4 | 86,060 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Purchase of securities on an exchange or from another person at price $ 2.59 per share. | 09 Sep 2024 | 25,000 | 212,295 (1%) | 0% | 2.6 | 64,750 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Other type of transaction at price $ 0.00 per share. | 24 May 2024 | 43,700 | 65,672 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 43,700 | 109,372 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Kelly Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2023 | 65,672 | 65,672 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 92,958 | 150,000 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 56,000 | 94,000 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 19,600 | 130,400 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 18,000 | 132,000 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 6,400 | 41 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 57,042 | 57,042 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 04 Apr 2022 | 10,000 | 197,295 (1%) | 0% | 3.2 | 32,400 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2022 | 10,000 | 20,500 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 30.04 per share. | 04 Apr 2022 | 10,000 | 187,295 (1%) | 0% | 30.0 | 300,395 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 20,000 | 30,500 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 03 Jan 2022 | 20,000 | 187,295 (1%) | 0% | 3.2 | 64,800 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2021 | 117,530 | 117,530 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2021 | 5,000 | 50,500 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 09 Mar 2021 | 5,000 | 172,295 (1%) | 0% | 3.2 | 16,200 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 35.42 per share. | 09 Mar 2021 | 3,388 | 168,907 (1%) | 0% | 35.4 | 119,995 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 36.33 per share. | 09 Mar 2021 | 1,612 | 167,295 (1%) | 0% | 36.3 | 58,556 | Common Stock |